कंपनी का अवलोकन
Azitra, Inc. (AZTR) operates as an early-stage clinical biopharmaceutical entity dedicated to developing novel therapies for precision dermatology. The company utilizes engineered proteins and topical live biotherapeutic products to address skin diseases within the United States market. This enterprise is categorized within the broader Healthcare sector, specifically functioning in the Biotechnology industry, which implies a focus on high-risk, high-reward research and development activities. The organization employs a small workforce of 13 individuals to execute its strategic initiatives. In terms of market valuation, the company holds a market capitalization of $3.79 million. The available financial data indicates that the annual revenue figure is not disclosed in the provided records, and the net income stands at a loss of $10,955,370. This limited scale, characterized by a market cap under $4 million and a lack of reported revenue, suggests that the company is in a pre-revenue or early-stage commercialization phase where capital allocation is primarily directed toward R&D rather than profit generation.
वित्तीय स्वास्थ्य
The financial statements reveal a revenue stream that is not quantifiable in the current reporting period, while the net income (TTM) reflects a significant deficit of $-10,955,370. The EBITDA for the trailing twelve months is recorded at $-10,828,596. The substantial gap between the negligible or unreported revenue and the heavy net loss indicates a cost structure dominated by research and development expenditures rather than operational overhead from sales. The company reports a free cash flow of $-6,947,441, which signifies a continuous cash burn rate that necessitates external financing to maintain operations. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported as 0.0%, reflecting the early-stage nature of the business where revenue has not yet scaled to cover fixed costs. On the balance sheet, the company holds $2.07 million in cash against total debt of $422,077. The debt-to-equity ratio is calculated at 11.10, indicating a highly leveraged position relative to shareholders' equity. Despite the high leverage metric, the current ratio stands at 2.83, suggesting that the company possesses sufficient current assets to cover its short-term liabilities multiple times over. The Return on Equity is -230.7%, and the Return on Assets is -110.7%, metrics that reveal that the existing capital base is currently generating negative returns due to the lack of profitable commercial operations.
मूल्यांकन आकलन
The P/E Ratio (TTM) is listed as N/A due to the negative earnings, while the Forward P/E is -0.45. The negative forward P/E implies that analysts or market participants are pricing in a future trajectory where the company is expected to remain unprofitable or requires significant restructuring to achieve positive earnings. The Price to Book ratio is 0.66, indicating that the market values the company's equity at a discount to its book value. This pricing suggests that the market does not assign a premium to the company's assets, likely due to the high uncertainty surrounding the commercialization of its biotherapeutic products. The Price to Sales ratio is N/A because the company has not generated sufficient revenue to establish a meaningful sales multiple. Additionally, the EV/EBITDA stands at -0.20, an alternative valuation metric that further underscores the company's current inability to generate positive earnings before interest, taxes, depreciation, and amortization. The stock's 52-week high is $2.67, and the 52-week low is $0.10. Without a specific current price provided in the facts, the trading range indicates extreme volatility within a $2.57 span. The Beta is -2.17, a value that is highly unusual and suggests an inverse correlation with the broader market or significant data irregularity in the provided metrics. This negative beta implies that the stock price moves counter to general market trends, although such a figure in a small-cap biotech context warrants careful scrutiny regarding its interpretation against standard market indices.
Growth & Income
The Revenue Growth (YoY) is N/A, and the Earnings Growth (YoY) is also N/A due to the absence of prior comparable revenue figures and negative earnings. Since revenue is N/A, it is impossible to calculate a growth rate, but the implication is that the company is in a stage where historical sales data for comparison does not exist. The company does not pay dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. Consequently, the company reinvests all available resources, including its $2.07 million cash reserve, directly into its research and development pipeline rather than distributing income to shareholders. The overall growth and income profile for Azitra, Inc. is characterized by a complete reliance on future product approvals and commercialization success rather than current income generation or historical growth rates. The negative Return on Assets and Equity further reinforce that the business model is currently focused on asset accumulation through R&D rather than value accretion for investors.